text
"[""\nXII. 상세표\n1. 연결대상 종속회사 현황(상세)\n☞ 본문 위치로 이동\n(단위 : 천원)\n상호\n설립일\n주소\n주요사업\n최근사업연도말자산총액\n지배관계 근거\n주요종속회사 여부\n셀트리온제약\n2000.11.17\n충청북도 청주시 청원군 오창읍 2산단로 82\n의약품 제조ㆍ판매\n641,643,568\xa0\n지분 50%초과보유\n해당\n셀트리온유럽\n2009.07.21\n4th Floor, 15 Basinghall Street, London, EC2V 5BR, UK\n바이오의약품 임상시험\n2\xa0\n지분 50%초과보유\n미해당\nCelltrion Global Safety Data Center\n2018.05.23\nUnit 2201, 22th floor, One Global Place, 5th Avenue Corner 25th Street, Bonifacio Global City, Taguig, 1634 Metro Manila, Philippines\n글로벌의약품 안전성 데이터 관리\n3,286,670\xa0\n지분 50%초과보유\n미해당\nCelltrion Biopharma\n2019.02.13\n1st Floor, 6 Lapp's Quay, Cork, T12 VY7W, Ireland\n바이오의약품 임상시험\n0\n지분 50%초과보유\n미해당\nShanghai Vcell Biotech(*1)\n2019.04.09\n上海市浦東新區南彙新城鎭芦潮港路1969號219室\n바이오의약품 임상시험 등 연구개발\n1,446,835\xa0\n지분 50%초과보유\n미해당\nCelltrion Asia Pacific PTE\n2020.08.12\n6 Eu Tong Sen Street #11-10C, The Central Singapore, 059817\n케미컬의약품 판매 및 연구개발\n364,606,829\xa0\n지분 50%초과보유\n해당\nCelltrion Healthcare ILAC SANAYI TICARET LIMITED SIRKETI(*2)\n2010.09.16\nPark Plaza, Maslak Mahallesi Eski Buyukdere Cad.No: 14 Kat 7D : 19 34396 Sarıyer, Istanbul, Turkey\n의약품 제조 및 도소매업\n56,221,910\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Hungary, Kft.(*2)\n2010.05.10\nVaci ut 1-3, WestEnd Office Building B torony, H-1062 Budapest, Hungary\n의약품 제조 및 도소매업\n1,290,432,441\xa0\n지분 50%초과보유\n해당\nCelltrion Healthcare Philippines Inc.(*2)\n2012.05.16\nUnit 2206 Philippine Axa Life Centre, Sen.Gil Puyat Avenue, 1200 Makati City, Philippines\n의약품 도소매업\n4,421,890\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Malaysia SDN BHD(*2)\n2012.06.13\nUnit 32-01, Level 32 Tower B, The Vertical Corporate Towers, Avenue 10 Bangsar South, No.8 Jalan Kerinchi, 59200 Kuala Lumpur\n의약품 도소매업\n611,615\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Hong Kong Limited(*2)\n2012.05.10\nSuite 3305, 33rd Floor, Tower 5, The Gateway,Harbour City, 15 Canton Road, Tsim Sha Tsui, Kowloon\n의약품 도소매업\n15,723,664\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare (Thailand) Co., Ltd.(*2)\n2012.05.25\nNo. 18 The Unicorn, Unit 1107-1111, 11thFloor Phayathai Road, Kwaeng Thungphayathai, Khet Ratchathewi, Bangkok\n의약품 도소매업\n50,979,399\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Distribuicao de Produtos Farmaceuticos do Brasil LTDA(*2)\n2012.07.13\nRua Santo Antonio, 175, Piso Terreo, Centro, Caieiras, Sao Paulo, Brazil\n의약품 도소매업\n124,823,810\xa0\n지분 50%초과보유\n해당\nCelltrion Healthcare Singapore Private Limited(*2)\n2012.06.01\n65, Chulia Street #41-02 OCBC Centre, Singapore 049513\n의약품 도소매업\n8,302,376\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Japan K.K.(*2)\n2014.07.09\n104－0033, Tokyo-to, Chuo-ku, Shinkawa 1-16-3, Sumitomo Fudosan Kayabacho Bldg. 3rd floor\n의약품 제조 및 도소매업\n39,868,290\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Taiwan Limited(*2)\n2016.11.10\n3F.-1, No. 97, Songren Rd., Xinyi Dist., Taipei City 110050, Taiwan (R.O.C.) \xa0(postal code : 110050)\n의약품 도소매업\n13,580,326\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Netherlands B.V.(*2)\n2018.02.06\nStrawinskylaan 625, 1077XX Amsterdam, Netherlands\n의약품 도소매업\n63,027,907\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Australia Pty Ltd(*2)\n2018.04.05\nSuite 1303 Level 13, 31 New Market Street, Sydney NSW 2000, Australia\n의약품 도소매업\n20,575,439\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Colombia S.A.S.(*2)\n2018.08.17\nCalle 37 No. 24-28, Bogota D.C., Colombia\n의약품 도소매업\n47,063,709\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Canada Ltd.(*2)\n2019.06.25\n6345 197 Street, Langley, Britishy Columbia, V2Y 1K8, Canada\n의약품 도소매업\n10,787,611\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare United Kingdom Limited.(*2)(*3)\n2018.11.19\nThe Switch, 1-7 The Grove, Slough, SL1 1QP, UK\n의약품 도소매업\n68,905,909\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Ireland Limited(*2)(*3)\n2018.11.23\nSuite 26, Arrow Building, Old Belgard Road, Tallaght, Dublin, D24 ND70, Ireland\n의약품 도소매업\n15,732,606\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Denmark ApS(*2)(*3)\n2018.11.27\nC/O Regus Fuglevangsvej 11 1962 Frederiksberg C, Denmark\n의약품 도소매업\n96,335\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Austria GmbH(*2)(*3)\n2018.12.21\nQBC 4, Am Belvedere 4, Vienna 1100, Austria\n의약품 도소매업\n129,992\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Deutschland GmbH(*2)(*3)\n2019.01.14\nRathausplatz 12, 61348 Bad Homburg vor der Hohe, Germany\n의약품 도소매업\n11,803,082\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Italy S.r.l(*2)(*3)\n2019.01.08\nVIA GALVANI LUIGI 24 CAP 20124, MILAN, Italy\n의약품 도소매업\n55,024,849\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Belgium Sprl.(*2)(*3)\n2019.01.15\nIkaroslaan 1, 1930 Zaventem, Belgium\n의약품 도소매업\n2,103,118\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Norway AS(*2)(*3)\n2019.03.04\nC/O Spaces Aker Brygge Fjordalleen 16 0250 OSLO, Norway\n의약품 도소매업\n117,646\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare France SAS(*2)(*3)\n2019.04.03\n14 rue Cambaceres, 75008 Paris, France\n의약품 도소매업\n136,109,502\xa0\n지분 50%초과보유\n해당\nCelltrion Healthcare Finland Oy(*2)(*3)\n2019.05.28\nc/o SPACES Mannerheiminaukio 1 A, 00100 Helsinki, Finland\n의약품 도소매업\n3,251,581\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare New Zealand Limited(*2)(*4)\n2018.10.25\nMoore Stephens Markhams Auckland, Floor 1, 103 Carlton Gore Road, Newmarket, Auckland 1023, NZ\n의약품 도소매업\n1,103,923\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare De Mexico S.A. de C.V.(*2)(*5)\n2018.12.20\nAdolfo Prieto 1213, Del Valle, Benito Juarez, Avenida Angel Urraza y Porfirio Diaz, Mexico\n의약품 도소매업\n29,248,337\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Chile SpA(*2)(*5)\n2018.12.18\nAv. Providencia, Nro. 1760, Depto 603, Provincia, Santiago, Chile\n의약품 도소매업\n1,663,580\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Peru S.A.C.(*2)(*5)\n2019.02.19\nAv. El Polo N° 670 Ofic. 301 Block A - Santiago de Surco, Peru\n의약품 도소매업\n7,562,032\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Argentina S.A.U.(*2)(*5)\n2019.01.17\nSarmiento 663. 3er. Piso. Buenos Aires City, Argentina\n의약품 도소매업\n293\xa0\n지분 50%초과보유\n미해당\nCelltrion USA, Inc.(*2)\n2018.07.26\n1 EVERTRUST PLAZA SUITE 1207 JERSEY CITY, NEW JERSEY 07302\n의약품 도소매업\n95,133,591\xa0\n지분 50%초과보유\n해당\nCelltrion Healthcare Czech Republic s.r.o.(*2)(*3)\n2022.08.04\nBucharova 2657/12, 158 00, Praha 5 - Stod?lky\n의약품 도소매업\n1,479,245\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Romania S.R.L.(*2)(*3)\n2022.11.10\nBucuresti Sectorul 1, Calea Floreasca, Nr. 169*A, Birou 2058-2059, Corp A, Etaj 4\n의약품 도소매업\n794,833\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Poland Republic s.r.o.(*2)(*3)\n2023.11.03\nUL.DUBOIS 114/116, 93-465 LODZ, Poland\n의약품 도소매업\n332,546\xa0\n지분 50%초과보유\n미해당\nCelltrion Swizerland GmbH(*3)(*6)\n2024.01.24\nc/o Claudia Stehli bei Liatowitsch & Partner Elisabethenstrasse 28 4051 Basel\n의약품 도소매업\n30,742\xa0\n지분 50%초과보유\n미해당\nCelltrion Farmaceutica(ESPANA),S.L.(*3)(*6)\n2024.03.01\nAvenida Diagonal 409 Pl. 3 ,08008 Barcelona, Barcelona\n의약품 도소매업\n243,651\xa0\n지분 50%초과보유\n미해당\nCelltrion Portugal, UNIPESSOAL LDA(*3)(*6)\n2024.02.28\nLisboa Concelho: Lisboa Freguesia: Avenidas Novas 1050 - 196 Lisboa\n의약품 도소매업\n110,070\xa0\n지분 50%초과보유\n미해당\nCelltrion Sweden AB(*3)(*6)\n2024.05.30\nGavlegatan 16, 113 30 STOCKHOLM\n의약품 도소매업\n261,399\xa0\n지분 50%초과보유\n미해당\n(*1) 전기 중 Celltrion Group Hongkong이 보유하고 있던 지분을 신규취득하였으며, 취득시 연결기업이 지배력을 보유하고 있다고 판단하여 연결기업의 종속기업에 추가되었습니다.\n(*2) 전기 중 셀트리온헬스케어를 흡수 합병함에 따라 추가되었습니다.\n(*3) Celltrion Healthcare Hungary, Kft.의 종속기업입니다.\n(*4) Celltrion Healthcare Australia Pty Ltd의 종속기업입니다.\n(*5) Celltrion Healthcare Colombia S.A.S의 종속기업입니다.\n(*6) 당기 중 신규 설립 하였습니다.\n2. 계열회사 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2024년 06월 30일\n)\n(단위 : 사)\n상장여부\n회사수\n기업명\n법인등록번호\n상장\n2\n(주)셀트리온\n135011-0034038\n(주)셀트리온제약\n110111-2112764\n비상장\n6\n(주)셀트리온홀딩스\n120111-0551178\n(주)셀트리온엔터테인먼트\n110111-4767757\n(주)셀트리온스킨큐어\n110111-1995723\n(주)티에스이엔씨\n120111-0379223\n(주)서린홀딩스\n110111-7727253\n(주)서원디앤디\n110111-7026332\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2024년 06월 30일\n)\n(단위 : 천원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n바이오톡스텍\n상장\n2009.07.28\n단순투자\n2,025,000\n1,631,134\xa0\n10.22\xa0\n10,047,786\xa0\n0\xa0\n0\xa0\n-2,185,720\xa0\n1,631,134\xa0\n10.22\n7,862,066\xa0\n92,358,194\xa0\n-1,790,399\xa0\nA&G Pharmaceutical, Inc.\n비상장\n2006.07.14\n단순투자\n2,676,548\n987,889\xa0\n16.51\xa0\n116,349\xa0\n0\xa0\n0\xa0\n0\xa0\n987,889\xa0\n16.51\n116,349\xa0\n6,289,820\xa0\n671,391\xa0\n매일방송\n비상장\n2011.03.17\n단순투자\n1,000,000\n250,981\xa0\n0.48\xa0\n1,475,167\xa0\n0\xa0\n0\xa0\n0\xa0\n250,981\xa0\n0.48\n1,475,167\xa0\n446,456,570\xa0\n9,913,458\xa0\n제이티비씨\n비상장\n2017.09.20\n단순투자\n500,000\n100,000\xa0\n0.09\xa0\n43,725\xa0\n0\xa0\n0\xa0\n0\xa0\n100,000\xa0\n0.09\n43,725\xa0\n417,518,925\xa0\n-71,672,378\xa0\nAbpro Corporation\n비상장\n2022.09.26\n단순투자\n2,816,797\n111,111\xa0\n0.65\xa0\n2,816,797\xa0\n0\xa0\n0\xa0\n0\xa0\n111,111\xa0\n0.65\n2,816,797\xa0\n4,325,937\xa0\n-15,281,129\xa0\nDantari\n비상장\n2022.07.01\n단순투자\n491,016\n910,615\xa0\n1.62\xa0\n343,711\xa0\n0\xa0\n0\xa0\n0\xa0\n910,615\xa0\n1.62\n343,711\xa0\n7,331,528\xa0\n-15,343,789\xa0\nTriunfo\n비상장\n2023.04.06\n단순투자\n-\n910,615\xa0\n1.46\xa0\n147,305\xa0\n0\xa0\n0\xa0\n0\xa0\n910,615\xa0\n1.46\n147,305\xa0\n1,425,572\xa0\n-7,174,537\xa0\n피노바이오\n비상장\n2022.10.31\n단순투자\n2,000,310\n66,900\xa0\n1.20\xa0\n2,000,310\xa0\n0\xa0\n0\xa0\n0\xa0\n66,900\xa0\n1.12\n2,000,310\xa0\n7,159,685\xa0\n-9,871,603\xa0\nHEM Pharma\n비상장\n2023.11.22\n단순투자\n1,000,006\n47,893\xa0\n0.77\xa0\n1,000,006\xa0\n0\xa0\n0\xa0\n0\xa0\n47,893\xa0\n0.77\n1,000,006\xa0\n27,823,768\xa0\n-11,666,505\xa0\n바스젠바이오\n비상장\n2023.04.24\n단순투자\n1,050,000\n7,000\xa0\n1.49\xa0\n1,050,000\xa0\n0\xa0\n0\xa0\n0\xa0\n7,000\xa0\n1.49\n1,050,000\xa0\n3,682,359\xa0\n-4,914,892\xa0\n프리미어 글로벌이노베이션 1호\n비상장\n2017.06.15\n단순투자\n250,000\n2,327\xa0\n6.67\xa0\n3,222,160\xa0\n-278\xa0\n-278,000\xa0\n-1,250,980\xa0\n2,049\xa0\n4.71\n1,693,180\xa0\n48,700,744\xa0\n2,552,364\xa0\n프리미어 글로벌이노베이션 2호\n비상장\n2020.11.05\n단순투자\n250,000\n4,357\xa0\n5.56\xa0\n4,151,199\xa0\n-452\xa0\n-405,851\xa0\n-101,629\xa0\n3,905\xa0\n5.56\n3,643,719\xa0\n75,163,949\xa0\n-1,757,199\xa0\n프리미어 글로벌이노베이션 3호\n비상장\n2024.06.28\n단순투자\n496,500\n0\xa0\n0.00\xa0\n0\xa0\n497\xa0\n496,500\xa0\n-17,744\xa0\n497\xa0\n1.92\n478,756\xa0\n25,455,659\xa0\n-755,458\xa0\n유안타 K 바이오백신 펀드\n비상장\n2024.04.29\n단순투자\n402,000\n0\xa0\n0.00\xa0\n0\xa0\n402,000,000\xa0\n402,000\xa0\n-52,255\xa0\n402,000,000\xa0\n6.67\n349,745\xa0\n6,028,054\xa0\n-764,258\xa0\n셀트리온 유럽\n비상장\n2009.07.21\n경영참여\n2\n1\xa0\n100.00\xa0\n2\xa0\n0\xa0\n0\xa0\n0\xa0\n1\xa0\n100.00\n2\xa0\n2\xa0\n0\xa0\n셀트리온제약\n상장\n2013.04.23\n경영참여\n50,057,259\n21,712,012\xa0\n54.81\xa0\n255,342,176\xa0\n1,085,600\xa0\n0\xa0\n0\xa0\n22,797,612\xa0\n54.81\n255,342,176\xa0\n641,643,568\xa0\n21,264,989\xa0\nCelltrion Global Safety Data Center\n비상장\n2018.05.23\n경영참여\n1,106,930\n580,563\xa0\n99.99\xa0\n1,204,581\xa0\n0\xa0\n0\xa0\n0\xa0\n580,563\xa0\n99.99\n1,204,581\xa0\n3,286,670\xa0\n35,264\xa0\nCelltrion Asia Pacific PTE\n비상장\n2020.11.23\n경영참여\n315,987,120\n283,600,000\xa0\n100.00\xa0\n315,987,120\xa0\n-138,000,000\xa0\n-190,509,000\xa0\n0\xa0\n145,600,000\xa0\n100.00\n125,478,120\xa0\n364,606,829\xa0\n-7,208,344\xa0\nVcell Shanghai Biotech\n비상장\n2023.01.19\n경영참여\n1,425,590\n0\xa0\n100.00\xa0\n1,425,590\xa0\n0\xa0\n0\xa0\n0\xa0\n0\xa0\n100.00\n1,425,590\xa0\n1,446,835\xa0\n-5,393\xa0\nCelltrion Healthcare ILAC SANAYI TICARET LIMITED SIRKETI\n비상장\n2023.12.28\n경영참여\n23,664,284\n1,337,866\xa0\n100.00\xa0\n15,505,212\xa0\n0\xa0\n0\xa0\n0\xa0\n1,337,866\xa0\n100.00\n15,505,212\xa0\n56,221,910\xa0\n-1,690,514\xa0\nCelltrion Healthcare Hungary, Kft.\n비상장\n2023.12.28\n경영참여\n704,771,752\n0\xa0\n100.00\xa0\n704,771,752\xa0\n0\xa0\n0\xa0\n0\xa0\n0\xa0\n100.00\n704,771,752\xa0\n1,290,432,441\xa0\n19,221,137\xa0\nCelltrion Healthcare Philippines Inc.\n비상장\n2023.12.28\n경영참여\n935,128\n389,995\xa0\n99.99\xa0\n935,128\xa0\n410,000\xa0\n955,710\xa0\n0\xa0\n799,995\xa0\n99.99\n1,890,838\xa0\n4,421,890\xa0\n120,206\xa0\nCelltrion Healthcare Malaysia SDN BHD\n비상장\n2023.12.28\n경영참여\n161,045\n538,336\xa0\n100.00\xa0\n161,045\xa0\n0\xa0\n0\xa0\n0\xa0\n538,336\xa0\n100.00\n161,045\xa0\n611,615\xa0\n30,655\xa0\nCelltrion Healthcare Hong Kong Limited\n비상장\n2023.12.28\n경영참여\n376,202\n2,586,895\xa0\n100.00\xa0\n376,202\xa0\n0\xa0\n0\xa0\n0\xa0\n2,586,895\xa0\n100.00\n376,202\xa0\n15,723,664\xa0\n542,177\xa0\nCelltrion Healthcare (Thailand) Co., Ltd.\n비상장\n2023.12.28\n경영참여\n2,586,240\n20,199,998\xa0\n99.99\xa0\n2,586,240\xa0\n0\xa0\n0\xa0\n0\xa0\n20,199,998\xa0\n100.00\n2,586,240\xa0\n50,979,399\xa0\n1,434,748\xa0\nCelltrion Healthcare Distribuicao deProdutos Farmaceuticos do Brasil LTDA\n비상장\n2023.12.28\n경영참여\n64,555,806\n14,692,902\xa0\n100.00\xa0\n64,555,806\xa0\n0\xa0\n0\xa0\n0\xa0\n14,692,902\xa0\n100.00\n64,555,806\xa0\n124,823,810\xa0\n30,686,271\xa0\nCelltrion Healthcare Singapore Private Limited\n비상장\n2023.12.28\n경영참여\n178,945\n200,000\xa0\n100.00\xa0\n178,944\xa0\n0\xa0\n0\xa0\n0\xa0\n200,000\xa0\n100.00\n178,944\xa0\n8,302,376\xa0\n123,713\xa0\nCelltrion Healthcare Japan K.K.\n비상장\n2023.12.28\n경영참여\n23,996,341\n484,060\xa0\n100.00\xa0\n23,996,341\xa0\n0\xa0\n0\xa0\n0\xa0\n484,060\xa0\n100.00\n23,996,341\xa0\n39,868,290\xa0\n944,427\xa0\nCelltrion Healthcare Taiwan Limited\n비상장\n2023.12.28\n경영참여\n-\n0\xa0\n100.00\xa0\n0\xa0\n0\xa0\n0\xa0\n0\xa0\n0\xa0\n100.00\n0\xa0\n13,580,326\xa0\n328,311\xa0\nCelltrion Healthcare Netherlands B.V.\n비상장\n2023.12.28\n경영참여\n224,538\n100,101\xa0\n100.00\xa0\n224,538\xa0\n0\xa0\n0\xa0\n0\xa0\n100,101\xa0\n100.00\n224,538\xa0\n63,027,907\xa0\n885,848\xa0\nCelltrion Healthcare Australia Pty Ltd\n비상장\n2023.12.28\n경영참여\n2,201,659\n4,764,010\xa0\n100.00\xa0\n2,201,659\xa0\n0\xa0\n0\xa0\n0\xa0\n4,764,010\xa0\n100.00\n2,201,659\xa0\n20,575,439\xa0\n5,384,581\xa0\nCelltrion Healthcare Colombia S.A.S.\n비상장\n2023.12.28\n경영참여\n18,647,246\n59,198,321\xa0\n100.00\xa0\n18,647,246\xa0\n0\xa0\n0\xa0\n0\xa0\n59,198,321\xa0\n100.00\n18,647,246\xa0\n47,063,709\xa0\n-1,649,817\xa0\nCelltrion Healthcare Canada Ltd.\n비상장\n2023.12.28\n경영참여\n196,078,894\n186,430,000\xa0\n100.00\xa0\n196,078,894\xa0\n50,000,000\xa0\n5,054,100\xa0\n0\xa0\n236,430,000\xa0\n100.00\n201,132,994\xa0\n10,787,611\xa0\n-10,783,918\xa0\nCelltrion USA, Inc.\n비상장\n2023.12.28\n경영참여\n3,254,735,180\n3,050\xa0\n100.00\xa0\n3,354,039,677\xa0\n0\xa0\n0\xa0\n0\xa0\n3,050\xa0\n100.00\n3,354,039,677\xa0\n95,133,591\xa0\n-20,644,112\xa0\n미래에셋셀트리온신성장투자조합 1호\n비상장\n2017.03.31\n일반투자\n6,250,000\n428\xa0\n50.00\xa0\n42,750,000\xa0\n-10\xa0\n-1,000,000\xa0\n0\xa0\n418\xa0\n50.00\n41,750,000\xa0\n105,516,402\xa0\n-7,436,819\xa0\n미래에셋셀트리온바이오생태계육성펀드\n비상장\n2021.12.30\n일반투자\n5,000,000\n20,000\xa0\n38.46\xa0\n20,000,000\xa0\n0\xa0\n0\xa0\n0\xa0\n20,000\xa0\n38.46\n20,000,000\xa0\n48,894,800\xa0\n-1,206,265\xa0\n아주-Solasta Life Science 4.0펀드\n비상장\n2022.05.16\n일반투자\n5,000,000\n25,000,000,000\xa0\n44.25\xa0\n25,000,000\xa0\n0\xa0\n0\xa0\n0\xa0\n25,000,000,000\xa0\n44.25\n25,000,000\xa0\n53,670,253\xa0\n-2,927,582\xa0\nIksuda Therapeutics Limited\n비상장\n2021.06.01\n경영참여\n9,031,863\n1,311,218\xa0\n22.38\xa0\n17,911,393\xa0\n0\xa0\n0\xa0\n0\xa0\n1,311,218\xa0\n22.38\n17,911,393\xa0\n31,801,554\xa0\n-18,854,116\xa0\n싸이런 테라퓨틱스\n비상장\n2023.05.01\n일반투자\n2,264,621\n88,359\xa0\n22.15\xa0\n2,460,221\xa0\n0\xa0\n0\xa0\n0\xa0\n88,359\xa0\n22.15\n2,460,221\xa0\n2,070,014\xa0\n-745,516\xa0\n셀트리온충북대바이오메딕스\n비상장\n2018.07.18\n경영참여\n100,000\n20,000\xa0\n50.00\xa0\n100,000\xa0\n0\xa0\n0\xa0\n0\xa0\n20,000\xa0\n50.00\n100,000\xa0\n118,613\xa0\n-9,410\xa0\n합 계\n25,603,288,937\xa0\r\n-\n5,092,854,282\xa0\r\n315,495,357\xa0\r\n-185,284,541\xa0\r\n-3,608,328\xa0\r\n25,918,784,294\xa0\r\n-\n4,903,961,413\xa0\r\n4,264,330,282\xa0\r\n-120,014,413\xa0\n""]"
